0001415889-22-008608.txt : 20220815 0001415889-22-008608.hdr.sgml : 20220815 20220815161639 ACCESSION NUMBER: 0001415889-22-008608 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220811 FILED AS OF DATE: 20220815 DATE AS OF CHANGE: 20220815 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Martin Samuel Bates CENTRAL INDEX KEY: 0001709024 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15006 FILM NUMBER: 221165833 MAIL ADDRESS: STREET 1: C/O CELLDEX THERAPEUTICS, INC. STREET 2: 53 FRONTAGE ROAD, SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Celldex Therapeutics, Inc. CENTRAL INDEX KEY: 0000744218 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 133191702 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 BUSINESS PHONE: 908-200-7500 MAIL ADDRESS: STREET 1: 53 FRONTAGE ROAD STREET 2: SUITE 220 CITY: HAMPTON STATE: NJ ZIP: 08827 FORMER COMPANY: FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC DATE OF NAME CHANGE: 19980828 FORMER COMPANY: FORMER CONFORMED NAME: T CELL SCIENCES INC DATE OF NAME CHANGE: 19920703 4 1 form4-08152022_010833.xml X0306 4 2022-08-11 0000744218 Celldex Therapeutics, Inc. CLDX 0001709024 Martin Samuel Bates C/O CELLDEX THERAPEUTICS, INC. 53 FRONTAGE ROAD, SUITE 220 HAMPTON NJ 08827 false true false false SVP AND CFO Common Stock 2022-08-11 4 M 0 2453 9.0165 A 26831 D Common Stock 2022-08-11 4 S 0 2453 37.0389 D 24378 D Common Stock 2022-08-12 4 M 0 3876 9.0165 A 28254 D Common Stock 2022-08-12 4 M 0 13671 2.78 A 41925 D Common Stock 2022-08-12 4 S 0 14261 36.7649 D 27664 D Common Stock 2022-08-12 4 S 0 2065 35.3766 D 25599 D Common Stock 2022-08-12 4 S 0 1221 34.6206 D 24378 D Incentive Stock Option (Right to Buy) 9.0165 2022-08-11 4 M 0 2453 0 D 2028-06-13 Common Stock 2453 7077 D Incentive Stock Option (Right to Buy) 9.0165 2022-08-12 4 M 0 3876 0 D 2028-06-13 Common Stock 3876 3201 D Incentive Stock Option (Right to Buy) 2.78 2022-08-12 4 M 0 13671 0 D 2029-06-19 Common Stock 13671 10750 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.00 to $37.26 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.23 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.82 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.31 to $34.81 per share, inclusive. The reporting person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. As of June 13, 2022, the option is fully vested. 25% vested on June 19, 2020 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters. /s/ Anthony S. Marucci, attorney-in-fact for Samuel Bates Martin 2022-08-15